What CONSTELLATION PHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Goldsmith Mark A | Director | Jul 15 | Disposition to Issuer · D | −89,857 | — | — | 0 |
| Audia James E | Director | Jul 15 | Disposition to Issuer · D | −25,434 | — | — | 0 |
| Raythatha Jigar | See Remarks | Jul 15 | Disposition to Issuer · D | −14,961 | — | — | 0 |
| Goldsmith Mark A | Director | Mar 04 | Exercise / conversion · M | +14,987 | — | — | 14,987 |
| Reeve Emma | Chief Financial Officer | Feb 22 | Open-market sale · S | −6,260 | $37.60 | −$235K | 0 |
| Reeve Emma | Chief Financial Officer | Feb 22 | Exercise / conversion · M | +6,260 | $8.04 | +$50.3K | 6,260 |
| Reeve Emma | Chief Financial Officer | Feb 19 | Open-market sale · S | −4,010 | $37.71 | −$151K | 0 |
| Reeve Emma | Chief Financial Officer | Feb 19 | Exercise / conversion · M | +4,010 | $8.04 | +$32.2K | 4,010 |
| Reeve Emma | Chief Financial Officer | Feb 18 | Open-market sale · S | −1,100 | $37.58 | −$41.3K | 0 |
| Reeve Emma | Chief Financial Officer | Feb 18 | Exercise / conversion · M | +1,100 | $8.04 | +$8.84K | 1,100 |
| Column Group L P | 10% owner | Feb 17 | Open-market sale · S | −10,000 | $36.95 | −$370K | 99,155 |
| Column Group L P | 10% owner | Feb 17 | Open-market sale · S | −10,000 | $36.95 | −$370K | 99,155 |
| Reeve Emma | Chief Financial Officer | Feb 17 | Exercise / conversion · M | +410 | $8.04 | +$3.3K | 410 |
| Reeve Emma | Chief Financial Officer | Feb 17 | Open-market sale · S | −410 | $37.56 | −$15.4K | 0 |
| Valentine Karen | See Remarks | Jan 19 | Open-market sale · S | −7,203 | $35.11 | −$253K | 0 |
| Valentine Karen | See Remarks | Jan 19 | Open-market sale · S | −1,227 | $33.69 | −$41.3K | 7,203 |
| Valentine Karen | See Remarks | Jan 19 | Open-market sale · S | −8,773 | $33.08 | −$290K | 8,430 |
| Valentine Karen | See Remarks | Jan 19 | Exercise / conversion · M | +17,203 | $11.50 | +$198K | 17,203 |
| Goldsmith Mark A | Director | Dec 25 | Gift · G | −64,173 | — | — | 74,870 |
| Goldsmith Mark A | Director | Dec 21 | Open-market sale · S | −4,020 | $35.02 | −$141K | 139,043 |
Loading...